Linnovation, Asia Medical and Philips China cooperation full swing in China Structural heart disease market

On March 1, 2021, Philips (Greater China), Asia Medical and Linnovation officially signed a memorandum of strategic cooperation. The two sides agreed to make full use of Philips's  innovation Cardiology solution, Asia Heart Group scientific research advantages and expert resources and Linnovation innovation platform's advantages in therapy innovation and expert resources with comprehensive cooperation in corelab, innovation platform and projects.

 

We should adhere to the idea that creation is the most important innovation for human beings and integrate diagnosis to therapy. It is believed that Philips, Asia Medical and  Linnovation will infiltrate and support each other in their respective advantageous fields, and fully support the rapid development of cardiovascular, especially structural heart disease, in China.

 

This is another milestone of Linnovation in China structural heart disease market after signing up cooperation deal with Valgen medtech company since 2020.

 

Linnovation （website）：http://www.linnovation.com.hk